Galderma introduces Cetaphil AM/PM Antioxidant Serums, a new science-driven defense and recovery system for sensitive skin Press release
Galderma’s Nemluvio® (nemolizumab) demonstrates long-term disease control in prurigo nodularis up to three years Press release
Galderma announces triple approval of new state-of-the-art Restylane® syringe in the EU, the U.S., and Canada, reaffirming the company’s position at the forefront of Injectable Aesthetics Press release
We Are All Sculptra: first-of-its-kind Galderma initiative to demonstrate how everyone can benefit from Sculptra’s regenerative properties Press release
Galderma expands Restylane® portfolio in Japan with launch of OBT™ hyaluronic acid injectables Restylane Defyne™ and Refyne™ Press release
Galderma announces U.S. FDA acceptance of RelabotulinumtoxinA Biologics License Application resubmission Press release
Galderma tackles menopause-related skin changes with global survey and clinical trial inclusivity Press release
Galderma unveils ‘Wake Up To Restylane’, underscoring Restylane as the ideal hyaluronic acid treatment for always-on natural beauty Press release
Galderma provides update on arbitration case regarding neuromodulator research and development partnership Press release
IMCAS 2026: Galderma showcases the latest scientific advances behind the industry’s broadest injectable aesthetics portfolio Press release
